PMID- 17122652
OWN - NLM
STAT- MEDLINE
DCOM- 20070119
LR  - 20161124
IS  - 1052-9551 (Print)
IS  - 1052-9551 (Linking)
VI  - 15
IP  - 4
DP  - 2006 Dec
TI  - Tissue pretreatment with formic acid might lower HercepTest scores in breast 
      cancer.
PG  - 237-42
AB  - Creutzfeldt-Jakob disease and other prion diseases are diseases with yet not 
      well-defined routes of transmission and infection. The safe processing of 
      potentially contaminated tissue material remains a challenge for histologic 
      laboratories. Formic acid pretreatment is considered to be effective in prion 
      inactivation. We evaluated the c-erbB2 and the hormone receptor-status in 
      potentially prion infectious breast cancer tissue after pretreatment with formic 
      acid. Paired breast cancer tissue samples were immunostained with commercially 
      available antibodies against c-erbB2, estrogen receptor, and progesterone 
      receptor with 1 tissue sample of each pair being pretreated with 98% formic acid. 
      Staining was evaluated either according to the HercepTest score or using an 
      immunoreactive score. Additionally, fluorescence in situ hybridization (FISH) 
      analyses were performed for 7 of these cases. Untreated tissues showed strong 
      circumferential staining for c-erbB2 (HercepTest score 3+), whereas the 
      membranous staining of the tissues pretreated with formic acid was significantly 
      weaker. FISH analyses showed no differences in both groups. The hormone receptor 
      expression was not significantly influenced and positivity was maintained in all 
      cases. In breast cancer patients, the pretreatment of tissue with formic acid for 
      prion-decontamination in the case of suspected Creutzfeldt-Jakob disease or other 
      prion diseases can lead to underestimation of the immunohistologically determined 
      c-erbB2 status. In these cases, a c-erbB2-FISH analysis should be performed. For 
      the immunostaining of hormone receptors in breast cancer, formic acid 
      pretreatment can be applied without negative effects on the sensitivity or 
      specificity of the assay.
FAU - Fritzsche, Florian R
AU  - Fritzsche FR
AD  - Institute of Pathology, Charite-Universitatmedizin Berlin, Charite Platz 1-3, 
      10117 Berlin.
FAU - Kristiansen, Glen
AU  - Kristiansen G
FAU - Boesl, Andreas
AU  - Boesl A
FAU - Burkhardt, Mick
AU  - Burkhardt M
FAU - Pahl, Stefan
AU  - Pahl S
FAU - Dankof, Anja
AU  - Dankof A
FAU - Dietel, Manfred
AU  - Dietel M
FAU - Dahl, Edgar
AU  - Dahl E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diagn Mol Pathol
JT  - Diagnostic molecular pathology : the American journal of surgical pathology, part 
      B
JID - 9204924
RN  - 0 (Formates)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 0YIW783RG1 (formic acid)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/chemistry/complications/genetics/*pathology
MH  - Creutzfeldt-Jakob Syndrome/*complications
MH  - Evaluation Studies as Topic
MH  - Female
MH  - *Formates
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Receptors, Estrogen/analysis
MH  - Receptors, Progesterone/analysis
MH  - Sensitivity and Specificity
MH  - *Specimen Handling/methods
EDAT- 2006/11/24 09:00
MHDA- 2007/01/20 09:00
CRDT- 2006/11/24 09:00
PHST- 2006/11/24 09:00 [pubmed]
PHST- 2007/01/20 09:00 [medline]
PHST- 2006/11/24 09:00 [entrez]
AID - 00019606-200612000-00007 [pii]
AID - 10.1097/01.pdm.0000213466.83516.5b [doi]
PST - ppublish
SO  - Diagn Mol Pathol. 2006 Dec;15(4):237-42. doi: 10.1097/01.pdm.0000213466.83516.5b.